Rice Hall James & Associates LLC boosted its position in MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) by 31.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 167,766 shares of the company’s stock after buying an additional 40,301 shares during the quarter. Rice Hall James & Associates LLC owned approximately 0.23% of MoonLake Immunotherapeutics worth $3,127,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently bought and sold shares of MLTX. Kestra Advisory Services LLC acquired a new position in MoonLake Immunotherapeutics during the 4th quarter worth approximately $26,000. Bank of America Corp DE raised its holdings in shares of MoonLake Immunotherapeutics by 64.7% in the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock valued at $32,000 after purchasing an additional 1,781 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of MoonLake Immunotherapeutics by 115.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock valued at $42,000 after purchasing an additional 3,166 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of MoonLake Immunotherapeutics by 45.4% in the fourth quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock worth $45,000 after purchasing an additional 1,069 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new stake in shares of MoonLake Immunotherapeutics in the fourth quarter worth $47,000. Institutional investors own 93.85% of the company’s stock.
Insider Buying and Selling
In other news, CEO Da Silva Jorge Santos sold 68,289 shares of the firm’s stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $20.02, for a total value of $1,367,145.78. Following the completion of the sale, the chief executive officer directly owned 2,774,893 shares of the company’s stock, valued at $55,553,357.86. This trade represents a 2.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kristian Reich sold 50,000 shares of MoonLake Immunotherapeutics stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $19.43, for a total value of $971,500.00. Following the transaction, the insider owned 2,824,551 shares of the company’s stock, valued at $54,881,025.93. This represents a 1.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 250,000 shares of company stock worth $4,919,138. Company insiders own 10.40% of the company’s stock.
Wall Street Analyst Weigh In
Get Our Latest Research Report on MLTX
MoonLake Immunotherapeutics Stock Performance
Shares of MLTX opened at $19.02 on Monday. The company has a market cap of $1.40 billion, a PE ratio of -4.91 and a beta of 1.04. The firm has a 50-day moving average of $18.97 and a 200-day moving average of $17.70. MoonLake Immunotherapeutics has a one year low of $5.95 and a one year high of $62.75. The company has a debt-to-equity ratio of 0.39, a current ratio of 8.60 and a quick ratio of 8.60.
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) last issued its earnings results on Monday, May 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.07). As a group, equities analysts forecast that MoonLake Immunotherapeutics will post -3.64 earnings per share for the current year.
MoonLake Immunotherapeutics Company Profile
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Featured Stories
- Five stocks we like better than MoonLake Immunotherapeutics
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
